Kolexia
Gyan Emmanuel Hématologie
Gyan Emmanuel
Hématologie
Centre hospitalier de Tours
Tours, France
465 Activités
1.1 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Leucémies Leucémie aigüe myéloïde Syndromes myélodysplasiques Leucémie myéloïde Lymphome B diffus à grandes cellules Lymphome à cellules du manteau Lymphome folliculaire Lymphome B

Collaborateurs

Voir plus
Gressin Remy
Gressin Remy
Hôpital Nord Grenoble, La Tronche, France
Le Gouill Steven
Le Gouill Steven
Clcc Institut Curie, Paris, France
Cartron Guillaume
Cartron Guillaume
Hôpital Saint-Éloi, Montpellier, France
Herault Olivier
Herault Olivier
Centre hospitalier de Tours, Tours, France

Industries

Voir plus
Novartis
22 collaboration(s)
Dernière en 2023
Janssen
19 collaboration(s)
Dernière en 2023
Roche
17 collaboration(s)
Dernière en 2023
Sanofi
14 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS): A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
Essai Clinique (BMS)   13 mars 2024
LyMa101: Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress.
Haematologica   07 mars 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Haematologica   22 février 2024
RAT-HEMATO : Return to Work After Malignant Hemopathy
Essai Clinique (CHU Angers)   13 février 2024
Deep and Durable Responses with Epcoritamab SC Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Data from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort
Abstracts from the 2024 Tandem Meetings of ASTCT and CIBMTR, February 21-24, 2024, San Antonio, Texas, USA   01 février 2024
Bienvenue à Tours !
Edimark   01 février 2024
VOYAGE: A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Essai Clinique (MacroGenics)   24 janvier 2024
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Essai Clinique (Institut Curie)   10 janvier 2024
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA: A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Essai Clinique (Celgene)   02 janvier 2024